Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Current Liabilities (2018 - 2026)

10x Genomics' Total Current Liabilities history spans 8 years, with the latest figure at $153.5 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 30.45% to $153.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.5 million, a 30.45% increase, with the full-year FY2025 number at $153.5 million, up 30.45% from a year prior.
  • Total Current Liabilities hit $153.5 million in Q4 2025 for 10x Genomics, up from $147.3 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TXG hit a ceiling of $153.5 million in Q4 2025 and a floor of $94.4 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $116.8 million across 5 years, with a median of $112.7 million in 2021.
  • The widest YoY moves for Total Current Liabilities: up 104.09% in 2021, down 31.05% in 2021.
  • Tracing TXG's Total Current Liabilities over 5 years: stood at $110.4 million in 2021, then increased by 18.67% to $131.0 million in 2022, then decreased by 2.9% to $127.2 million in 2023, then fell by 7.49% to $117.6 million in 2024, then surged by 30.45% to $153.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for TXG at $153.5 million in Q4 2025, $147.3 million in Q3 2025, and $112.2 million in Q2 2025.